Ziopharm oncology inc (ZIOP)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Cash flows from operating activities:
Net loss

-18,293

-15,746

-73,996

-14,620

-13,434

-12,481

-12,585

-12,031

-16,020

-13,273

-12,701

-12,862

-15,487

-11,224

-10,854

-131,200

-12,019

-9,476

-18,170

-14,211

-78,231

-10,401

-6,093

-5,576

-9,711

-30,225

-17,824

-23,613

-24,470

-13,244

-802

-10,724

-39,008

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

142

176

157

156

140

163

157

138

117

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation

1,940

1,600

1,486

2,799

1,456

684

1,480

1,711

3,659

2,289

2,083

2,058

2,024

2,358

2,019

2,066

2,009

1,943

1,477

3,484

1,093

1,160

1,148

1,212

1,223

1,398

1,192

1,078

1,212

859

586

612

702

Depreciation and amortization

-

-

-

-

-

-

-

-

-

-

92

88

79

-

72

83

72

-

59

114

122

123

122

93

124

192

201

147

118

96

77

58

37

Bonus paid in common stock, net

-

-

-

-

630

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

194

5,847

5,600

82

8,566

3,945

-650

-5,811

12,006

4,542

2,115

-11,080

Common stock issued in exchange for license agreement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

67,285

-

-

-

-

-

-

-

-

0

0

0

17,457

Change in fair value of derivative liabilities

-

-

-

-

-

112

-165

183

28

-3

202

66

-1,560

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of common stock in a license agreement

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

87

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in operating assets and liabilities:
(Increase) decrease in:
Receivables

-2,548

-111

1,981

605

-1,009

843

357

646

-1

6

-31

-23

46

-4

10

-1,045

614

77

279

28

-83

-

176

5

-118

45

13

0

-79

-

-

-

5,000

Prepaid expenses and other current assets

-2,585

-1,318

2,903

-914

1,058

6,669

2,486

-9,064

1,172

-10,652

2,577

1,657

2,426

2,841

3,279

3,207

3,125

3,085

3,827

3,584

-282

-345

493

-598

-359

-323

-1,816

-1,752

9,490

1,870

-1,573

82

510

Right of use asset

-193

-

-

-

1,589

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deposits

-

0

0

0

-2

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

8

-8

0

4

Other noncurrent assets

556

1

-4,760

-1,855

-2,817

-8,626

-3,763

7,957

490

-

-

-

-

-

0

-6

5

-

-

-

-

-22

0

-4

-11

183

-6

30

23

925

-1,037

526

-7

Increase (decrease) in:
Accounts payable

-510

-20

-15

82

152

-561

681

-18

-3,811

2,893

1,443

-145

70

-1,658

-217

123

-100

-2,146

1,012

2,362

-1,224

51

1,506

-131

156

-2,739

2,779

-515

257

-433

376

-69

822

Accrued expenses

2,206

915

774

1,965

-1,929

-613

713

-215

-1,030

-202

756

-1,331

1,577

1,745

-29

-1,189

-324

-9,232

9,387

532

1,037

-620

31

2,021

-605

-166

1,180

3,968

713

2,032

2,705

2,222

1,324

Deferred revenue

-

-

-

-

-

0

0

0

-146

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Contract liabilities

-

-

-

-

-

-

-

-

-

-

-1,598

-1,597

-1,597

-

-1,598

-1,697

-1,969

-1,669

55,631

-272

-272

-340

-633

-200

-200

-200

-200

-200

-200

-200

-200

-200

4,933

Deferred rent

-

-17

0

0

17

-13

-38

-37

-37

-37

-37

-34

-31

-58

-83

-148

-91

-120

-88

-89

108

-59

-56

-51

-47

18

54

39

133

97

17

2

-7

Lease liabilities

-161

-

-

-

1,559

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-9,906

-11,608

-10,927

-8,087

-10,232

-11,819

-8,507

-10,174

-18,957

-12,156

-12,713

-15,523

-14,277

-13,064

-14,109

-15,073

-16,079

-23,802

45,203

-11,694

-9,717

-9,870

-10,491

-7,635

-8,654

-21,500

-14,707

-16,765

-25,860

-13,750

-11,096

-5,822

-8,167

Cash flows from investing activities:
Purchases of property and equipment

513

100

107

67

10

-86

169

226

150

276

76

27

358

82

212

100

157

387

3

5

17

0

94

97

2

77

375

953

154

350

414

165

227

Net cash used in investing activities

-513

-100

-107

-67

-10

86

-169

-226

-150

-276

-76

-27

-358

-82

-212

-100

-157

-387

-3

-5

-17

0

-94

-97

-2

-77

-375

-953

-154

-350

-414

-165

-227

Cash flows from financing activities:
Proceeds from exercise of stock options

4

-

-

-

-

-

-

-

-

-11

1

69

29

163

0

184

367

1,202

226

599

2,541

63

6

348

969

-

-

-

-

76

55

125

724

Issuance of common stock in connection with a public offering, net

88,661

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of common stock in connection with at the market offerings, net

13,015

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repurchase of common stock

-

-

-

-

-

347

0

544

731

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

132

-

-

-

-

196

0

0

78

Proceeds from issuance of common stock, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

94,320

-

-

-

-

0

0

1

49,169

0

0

0

71,207

Repurchase of restricted common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

851

2

-

133

0

246

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of common stock upon exercise of warrants, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

120

70

140

0

106

12,107

186

Net cash provided by financing activities

101,680

-

-

-

-

41,346

0

-304

-731

-1,028

1

46,297

29

-484

0

-669

365

1,063

93

565

96,615

6,551

3,706

348

837

-450

24

101

49,309

-120

161

12,232

72,039

Net increase (decrease) in cash and cash equivalents, and restricted cash

91,261

-8,678

44,856

-7,924

-10,242

29,613

-8,676

-10,704

-19,838

-13,460

-12,788

30,747

-14,606

-13,630

-14,321

-15,842

-15,871

-23,126

45,293

-11,134

86,881

-3,319

-6,879

-7,384

-7,819

-22,027

-15,058

-17,617

23,295

-14,220

-11,349

6,245

63,645

Supplementary disclosure of cash flow information:
Compensation paid in restricted stock, gross

-

-

-

-

1,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Property and equipment included in accrued expenses

2,303

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid for interest

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Cash paid for income taxes

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Supplementary disclosure of noncash investing and financing activities:
Exercise of liability-classified warrants to common shares

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

370

42

0

38

56

209

Issuance of stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

67,285

-

-

-

-

-

-

-

-

-

-

-

-

Series 1 Preferred Stock
Change in fair value of derivative liabilities

-

-

-

-

-

-

0

-27

28

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of dividends in preferred stock

-

-

-

-

-

342

6,074

5,462

5,120

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-